2. Has received more than 1 prior line of chemotherapy for advanced or metastatic adenocarcinoma of the lung. Note: Patients may have received additional prior radiotherapy or chemotherapy in the adjuvant setting, providing it was completed at least 6 months prior to start of study treatment.